Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization
Shmuel H. Klang, Ariel Hammerman, Nicky Liebermann, Noa Efrat, Julie Doberne, John Hornberger
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization'. Together they form a unique fingerprint.